These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 29064651)

  • 61. Transcutaneous tibial nerve home stimulation for overactive bladder in women with Parkinson's disease: A randomized clinical trial.
    Araujo TG; Schmidt AP; Sanches PRS; Silva Junior DP; Rieder CRM; Ramos JGL
    Neurourol Urodyn; 2021 Jan; 40(1):538-548. PubMed ID: 33326648
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Is the addition of vaginal electrical stimulation to transcutaneous tibial nerve electrical stimulation more effective for overactive bladder treatment? A randomized controlled trial.
    Bacchi Ambrosano Giarreta F; Milhem Haddad J; Souza de Carvalho Fusco HC; Chada Baracat E; Casarotto RA; Alves Gonçalves Ferreira E
    Actas Urol Esp (Engl Ed); 2021; 45(1):64-72. PubMed ID: 32660872
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Treatment patterns and costs among patients with OAB treated with combination oral therapy, sacral nerve stimulation, percutaneous tibial nerve stimulation, or onabotulinumtoxinA in the United States.
    Kraus SR; Shiozawa A; Szabo SM; Qian C; Rogula B; Hairston J
    Neurourol Urodyn; 2020 Nov; 39(8):2206-2222. PubMed ID: 32827230
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Transcutaneous posterior tibial nerve electrostimulation with low dose trospium chloride: Could it be used as a second line treatment of overactive bladder in females.
    Abulseoud A; Moussa A; Abdelfattah G; Ibrahim I; Saba E; Hassouna M
    Neurourol Urodyn; 2018 Feb; 37(2):842-848. PubMed ID: 28792105
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Contemporary Patterns of Third-line Treatments for Privately Insured Individuals With Overactive Bladder in the United States.
    Jiang J; Patil D; Traore EJ; Hammett J; Filson CP
    Urology; 2020 Aug; 142():87-93. PubMed ID: 32437771
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial.
    Peters KM; Carrico DJ; Perez-Marrero RA; Khan AU; Wooldridge LS; Davis GL; Macdiarmid SA
    J Urol; 2010 Apr; 183(4):1438-43. PubMed ID: 20171677
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Percutaneous tibial nerve stimulation maintenance therapy for overactive bladder in women: long-term success rates and adherence.
    Jung CE; Menefee SA; Diwadkar GB
    Int Urogynecol J; 2021 Mar; 32(3):617-625. PubMed ID: 32572541
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Percutaneous Tibial Nerve Stimulation (PTNS) efficacy in the treatment of lower urinary tract dysfunctions: a systematic review.
    Gaziev G; Topazio L; Iacovelli V; Asimakopoulos A; Di Santo A; De Nunzio C; Finazzi-Agrò E
    BMC Urol; 2013 Nov; 13():61. PubMed ID: 24274173
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The efficacy of posterior tibial nerve stimulation for the treatment of overactive bladder in women: a systematic review.
    Levin PJ; Wu JM; Kawasaki A; Weidner AC; Amundsen CL
    Int Urogynecol J; 2012 Nov; 23(11):1591-7. PubMed ID: 22411208
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Transcutaneous Tibial Nerve Stimulation in the Management of Overactive Bladder: A Scoping Review.
    Sayner AM; Rogers F; Tran J; Jovanovic E; Henningham L; Nahon I
    Neuromodulation; 2022 Dec; 25(8):1086-1096. PubMed ID: 35688702
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
    Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
    Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Patient preferences for treating refractory overactive bladder in the UK.
    Hashim H; Beusterien K; Bridges JF; Amos K; Cardozo L
    Int Urol Nephrol; 2015 Oct; 47(10):1619-27. PubMed ID: 26347077
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Cognitive functions and health-related quality of life in men with benign prostatic hyperplasia and symptoms of overactive bladder when treated with a combination of tamsulosin and solifenacin in a higher dosage.
    Kosilov K; Kuzina I; Kuznetsov V; Gainullina Y; Kosilova L; Prokofyeva A; Loparev S
    Aging Male; 2018 Jun; 21(2):121-129. PubMed ID: 29113548
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Long-term durability of percutaneous tibial nerve stimulation for the treatment of overactive bladder.
    MacDiarmid SA; Peters KM; Shobeiri SA; Wooldridge LS; Rovner ES; Leong FC; Siegel SW; Tate SB; Feagins BA
    J Urol; 2010 Jan; 183(1):234-40. PubMed ID: 19913821
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
    Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
    Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Development of an implant technique and early experience using a novel implantable pulse generator with a quadripolar electrode array at the tibial nerve for refractory overactive bladder.
    Sirls LT; Schonhoff A; Waldvogel A; Peters KM
    Neurourol Urodyn; 2023 Feb; 42(2):427-435. PubMed ID: 36573835
    [TBL] [Abstract][Full Text] [Related]  

  • 77. 8 versus 12 weeks of percutaneous tibial nerve stimulation and response predictors for overactive bladder.
    Jung CE; Menefee SA; Diwadkar GB
    Int Urogynecol J; 2020 May; 31(5):905-914. PubMed ID: 31927598
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [What to do if percutaneous tibial nerve stimulation (PTNS) works? A pilot study on home-based transcutaneous tibial nerve stimulation].
    Maurelli V; Petta F; Carsillo G; Miano R; Lamorte F; Perugia C; Finazzi Agrò E
    Urologia; 2012 Dec; 79 Suppl 19():86-90. PubMed ID: 22729604
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Comparing the Efficacy of OnabotulinumtoxinA, Sacral Neuromodulation, and Peripheral Tibial Nerve Stimulation as Third Line Treatment for the Management of Overactive Bladder Symptoms in Adults: Systematic Review and Network Meta-Analysis.
    Lo CW; Wu MY; Yang SS; Jaw FS; Chang SJ
    Toxins (Basel); 2020 Feb; 12(2):. PubMed ID: 32085542
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Neuromodulative treatment with percutaneous tibial nerve stimulation for intractable detrusor instability: outcomes following a shortened 6-week protocol.
    Yoong W; Ridout AE; Damodaram M; Dadswell R
    BJU Int; 2010 Dec; 106(11):1673-6. PubMed ID: 20590544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.